HRS5091
/ Jiangsu Hengrui Pharma
- LARVOL DELTA
Home
Next
Prev
1 to 4
Of
4
Go to page
1
December 23, 2022
A Pharmacokinetic Study to Evaluate the Drug Interaction Between HRS5091 and Probe Drugs in Healthy Volunteers
(clinicaltrials.gov)
- P1 | N=22 | Completed | Sponsor: Jiangsu HengRui Medicine Co., Ltd. | Not yet recruiting ➔ Completed
Trial completion • Hepatitis B • Hepatology • Infectious Disease • Inflammation
March 10, 2022
A Pharmacokinetic Study to Evaluate the Drug Interaction Between HRS5091 and Probe Drugs in Healthy Volunteers
(clinicaltrials.gov)
- P1 | N=22 | Not yet recruiting | Sponsor: Jiangsu HengRui Medicine Co., Ltd.
New P1 trial • Hepatitis B • Hepatology • Infectious Disease • Inflammation
October 22, 2021
A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Food Effect of Oral HRS5091 in Healthy Subjects and Chronic Hepatitis B Patients
(clinicaltrials.gov)
- P1; N=108; Active, not recruiting; Sponsor: Jiangsu HengRui Medicine Co., Ltd.; Not yet recruiting ➔ Active, not recruiting
Clinical • Enrollment closed • Hepatitis B • Hepatology • Infectious Disease • Inflammation
July 21, 2020
A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Food Effect of Oral HRS5091 in Healthy Subjects and Chronic Hepatitis B Patients
(clinicaltrials.gov)
- P1; N=98; Not yet recruiting; Sponsor: Jiangsu HengRui Medicine Co., Ltd.
Clinical • New P1 trial • Hepatitis B • Infectious Disease
1 to 4
Of
4
Go to page
1